Introduction

FDA contracted with the management consulting firm Eagle Hill Consulting to conduct this survey as an assessment of the Total Product Life Cycle (TPLC) Advisory Program (TAP) Pilot.

Please provide your feedback by answering the following questions. All responses will be kept confidential. Completing this survey should take approximately 20 minutes.

Your participation / non-participation is completely voluntary, and your responses will not have an effect on your eligibility for receipt of any FDA services. In instances where respondent identity is needed (e.g., for follow-up of non-respondents), this information collection fully complies with all aspects of the Privacy Act and data will be kept private to the fullest extent allowed by law.

Paperwork Reduction Act Statement:

OMB Control No. 0910-NEW Expiration date:

According to the Paperwork Reduction Act of 1995, an agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a valid OMB control number. The valid OMB control number for this information collection is 0910-NEW. The time required to complete this information collection is estimated to average 20 minutes per response, including the time to review instructions and completing the survey. Send comments regarding this burden estimate or any other aspects of this collection of information, including suggestions for reducing burden to PRAStaff@fda.hhs.gov.

Demographics

* 1. Please select your organization type below.
Professional Society
Patient Organization
Payer Subject-matter Expert (SME)
Other (please specify)
* 2. What type of role do you hold within your organization?
Member
Executive
Scientific/Technical
Advocacy
Education
Regulatory
Clinical
Quality
Operations
Coding/Payment/Coverage
Other (please specify)

Participation in Interactions

FDA with one or more organizations. Sponsors are medical device companies that have been accepted to participate in the TAP Pilot.
Did you or your organization engage in any TAP interactions with sponsors through the TAP Pilot?
Yes
○ No

Satisfaction with Interactions

* 4. How satisfied or dissatisfied was your organization with each of the following aspects of FDA-facilitated interactions with **sponsors** through the TAP Pilot?

	Very satisfied	Satisfied	Neither satisfied nor dissatisfied	Dissatisfied	Very dissatisfied
Quality					
Frequency					
Efficiency					
Timeliness					
* 5. Were intera Too frequent	ctions too freque	ent, too seldo	m, or just about r	right?	
O Too seldom					
Ust about rig	ht				

General TAP Participation

st 6. How much do you agree or disagree with the following statement: TAP interactions with sponsors were highly collaborative .
Strongly agree
Agree
Neither agree nor disagree
Oisagree Oisagree
Strongly disagree
* 7. How much do you agree or disagree that participating in TAP is a value-add for your organization? Strongly agree Agree Neither agree nor disagree Disagree Strongly disagree

General TAP Participation

\ast 8. In which of the following ways do you or your organization benefit from participation in the TAP Pilot? Please select all that apply.
Increased opportunities to build relationships with sponsors.
Increased opportunities to build relationships with FDA.
Improved understanding of the pre-market medical device review process.
Increased awareness of emerging technologies in medicine.
Increased awareness of how my stakeholder input can impact/influence the device development process.
Greater influence in the device development process.
Other (please specify)
None of the above

General TAP Participation

9. Approximately how many employees at your organization are currently in	ivolved in
participating in the TAP Pilot?	

participating in the		pioyees at yo	our organizat	ion are curre	entry involved	. 111
Enter answer as a v	vhole numbe	er.				
10. Approximately participating in to 0-8 hours 9-16 hours	=			average does	a given emp	loyee spend
9-16 hours						
25-32 hours						
33-40 hours						
41 hours or mo	ore					
11. How helpful or unhelpful were each of the following in improving your organizatio understanding of how to get the most value from the TAP Pilot. Neither helpful			ation's			
	Very helpful	Helpful	nor unhelpful	Somewhat unhelpful	Very unhelpful	N/A
Materials provided by FDA	\bigcirc				\bigcirc	
Email exchanges between your organization and FDA	\bigcirc			\bigcirc		\bigcirc
TAP webpage on fda.gov	\bigcirc	\bigcirc	\bigcirc		\bigcirc	
Meetings and phone calls with FDA staff	\bigcirc		\bigcirc	\circ	\bigcirc	\bigcirc

Concluding Remarks

12. What suggestion	ns do you have for how FDA could make TA	P interactions more valuable?
	<i>A</i>	
13. Please provide a	any other comments or feedback for FDA.	
=	ng to participate in a follow-up interview abo and email address below.	out the TAP Pilot, please
Name		
Company		
Email Address		
Phone Number		

Rationale for No Interactions

15. Please describe why you have NOT had any interactions in the TAP Pilot thus far.
Recently joined the TAP Pilot.
Not prepared for interactions.
Scheduling difficulties.
Sponsor failed to follow up to have interaction.
Other organizational priorities.
Interaction request not received.
Other (please specify)